scholarly journals Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage

2005 ◽  
Vol 94 (3) ◽  
pp. 271-278 ◽  
Author(s):  
P. Diprose ◽  
M.J. Herbertson ◽  
D. O’Shaughnessy ◽  
C.D. Deakin ◽  
R.S. Gill
Keyword(s):  
Cardiac Surgery ◽  
Controlled Trial ◽  
Cell Salvage ◽  
Double Blind ◽  
Allogeneic Transfusion ◽  
Double Blind Placebo

scholarly journals Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhong-Liang Dai ◽  
Yi-Feng Song ◽  
Ya Tian ◽  
Yin Li ◽  
Miao Lin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Surgery ◽  
Elderly Patients ◽  
Primary Endpoint ◽  
Myocardial Ischaemia ◽  
Cardiovascular Events ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Coronary Events

Abstract Background Trimetazidine (TMZ) pretreatment protects cardiomyocytes during cardiac surgery. TMZ may protect elderly patients with ischaemic heart disease (IHD) undergoing non-cardiac surgery. Methods This was a randomized, double-blind, placebo-controlled trial (registration #ChiCTR1900025018) of patients with IHD scheduled to undergo non-cardiac surgery at Shenzhen People’s Hospital (Shenzhen, Guangdong Province, China) between June 2014 and September 2015, randomized to 60 mg TMZ or placebo 12 h before surgery. The primary endpoint was the occurrence of in-hospital cardiovascular events. The secondary endpoints were myocardial ischaemia on five-lead electrocardiogram (cECG), cardiac troponin I (cTnI) elevation, cardiac death, acute coronary events, heart failure, and arrhythmia requiring treatments. Results Compared with the placebo group, the TMZ group showed a lower occurrence of in-hospital cardiovascular events (primary endpoint, 20.0% vs. 37.5%, P = 0.02), myocardial ischaemia (15.0% vs. 32.5%, P < 0.01), cTnI elevation (2.5% vs. 10%, P < 0.01), acute coronary events (10.0% vs. 20.0%, P < 0.05), heart failure (0% vs. 2.5%, P < 0.05), and arrhythmia requiring treatment (17.5% vs. 35.0%, P < 0.05). There was no acute myocardial infarction during the 30-day postoperative period. Conclusions In elderly patients with IHD undergoing non-cardiac surgery, TMZ pretreatment was associated with myocardial protective effects. Trial registration The trial was prospectively registered at http://www.chictr.org.cn/showproj.aspx?proj=41909 with registration number [ChiCTR1900025018] (7/8/2019).

scholarly journals Effect of Gabapentin on Pain after Cardiac Surgery: A Randomised, Double-Blind, Placebo-Controlled Trial

2010 ◽  
Vol 38 (3) ◽  
pp. 445-451 ◽  
Author(s):  
I. L. Rapchuk ◽  
L. O'Connell ◽  
C. D. Liessmann ◽  
H. R. Cornelissen ◽  
J. F. Fraser
Keyword(s):  
Cardiac Surgery ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial

The Lancet ◽  
2016 ◽  
Vol 388 (10054) ◽  
pp. 1893-1902 ◽  
Author(s):  
Xian Su ◽  
Zhao-Ting Meng ◽  
Xin-Hai Wu ◽  
Fan Cui ◽  
Hong-Liang Li ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Elderly Patients ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

Effect of Dexamethasone on Atrial Fibrillation After Cardiac Surgery: Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

2007 ◽  
Vol 21 (1) ◽  
pp. 68-75 ◽  
Author(s):  
Jean-Pierre Yared ◽  
Mohamed H. Bakri ◽  
Serpil C. Erzurum ◽  
Christine S. Moravec ◽  
Daniel M. Laskowski ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Cardiac Surgery ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document